期刊文献+

系统性红斑狼疮合并肺动脉高压十年住院病例分析 被引量:6

Systemic lupus erythematosus associated pulmonary arterial hypertension: results from lO-year inpa- tient cases analysis in a single center
原文传递
导出
摘要 目的研究系统性红斑狼疮(SEE)合并肺动脉高压患者的临床特点和诊治现状。方法对仁济医院风湿病科2001--2010年间住院患者进行分析随访。根据首诊心脏彩色多普勒超声估测肺动脉收缩压分为A组[≤70mmHg(1mmHg=0.133kPa)]和B组(〉70mmHg)。用Pearson相关分析研究狼疮活动性与肺动脉高压的关系,以X^2检验及Wileoxon检验不同组别的生存曲线差异。结果共有155例患者184次入院记录,占同期狼疮住院患者的4.16%。患者主要特点有:雷诺现象(47.3%)、心包积液(41.9%)和抗RNP抗体阳性(55.4%)。随访例数为132例,47例(35.6%)患者死亡,A组9例(19.1%),B组38例(80.9%)。A组患者肺动脉收缩压与狼疮活动指数呈正相关。单因素分析显示环磷酰胺(P〈0.05)和肺动脉高压靶向治疗药(P〈0.01)与疗效相关。以Logistic回归分析则仅有靶向治疗药与疗效相关(P〈0.01)。应用肺高压靶向药物能显著提高重症患者的1年期生存率。结论本病主要临床特点包括雷诺现象、心包积液和抗RNP抗体阳性。重症患者与狼疮活动性无相关性。肺动脉高压靶向药物疗效确切,环磷酰胺治疗对部分患者有效。重症患者联用环磷酰胺与肺动脉高压靶向药能显著改善预后。 Objective To investigate the clinical characteristics and current condition of treatment for systemic lupus erythematosus (SLE) associated pulmonary arterial hypertension (PAH). Methods 10-year inpatients cases were reviewed and fallowed up. Cases were divided into 2 groups: group A: patients with baseline pulmonary arterial systolic pressure (PASP) lower than 70 mmHg; group B: patients with baseline PASP higher than 70 mm Hg. Pearson's correlation analysis, Chi-square test, Logistic regression, Cox-Mantel and Wilcoxon test were used for statistical analysis. Results There were totally 155 cases with 184 records of admission which accounted for 4.16% among total lupus cases. The main clinical characteristics included Raynaud's phenomenon (47.3%), pericardial effusion (41.9%) and high titer of anti-RNP antibody (55.4%). There were 132 cases enrolled for prognostic statistical analysis. There were 47 cases of death (35.6%) in total, among which 9 cases (19.1%) were in group A and 38 cases (80.9%) were in group B. In group A, there was a positive correlation between PASP and lupus disease activity index score. Single therapy analysis by Chi-square test showed that cyclophosphamide (CTX) (P〈0.05) and PAH targeted drugs (P〈0.01) were significantly associated with favorable outcome but logistic regressive analysis only confirmed the efficacy of target drugs (P〈0.01). PAH target drugs significantly improved the one year survival rate of the severe cases. Conclusion The main clinical characteristics of SLE associated PAH include Raynaud's phenomenon, pericardial effusion and positive anti-RNP antibody. The severity of PAH may not be related to lupus disease activity. PAH targeted drugs are effective in SLE-PAH. CTX may be effective in some cases. For severe cases, the combination therapy of CTX and PAH targeted drugs could significantly improve the prognosis.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2013年第1期16-19,共4页 Chinese Journal of Rheumatology
关键词 红斑狼疮 系统性 高血压 肺性 免疫抑制剂 靶向治疗 Lupus erythematosus, systemic Hypertension, pulmonary Immunosuppressive agents Target treatment
  • 相关文献

参考文献10

  • 1Hayes GB,Oudiz RJ.肺动脉高压康复指南.荆志成,译.3版.北京:人民军医出版社,2008:36.
  • 2Amaud L, Agard C, Haroche J, et al. Pulmonary arterial hypertension in systemic lupus erythematosus. Rev Med Intern, 2011, 32: 689-697.
  • 3董馨,郑毅,陈曦.系统性红斑狼疮合并肺动脉高压23例临床分析[J].中华风湿病学杂志,2007,11(10):609-612. 被引量:5
  • 4Chung SM, Lee CK, Lee EY, et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol, 2006, 25: 866-872.
  • 5Kasparian A, Floros A, Gialafos E, et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus, 2007, 16: 505-508.
  • 6Lian F, Chen D, Wang Y, et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int, 2012, 32: 1727-1731.
  • 7Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three eases. Arthritis Rheum, 2008, 58: 521-531.
  • 8Miyamichi-Yamamoto S Fukumoto Y, Sugimura K, et al. Intentherapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J, 2011, 75 : 2668-2674.
  • 9Mok MY, Tsang PL, Lain YM, et al. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus, 2007, 16: 279-285.
  • 10Denton GP, Pope JE, Peter HH, et al. Long-term effects of Bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis, 2008, 67: 1222-1228.

二级参考文献8

  • 1Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis, 2002, 45: 225-234.
  • 2David B, Steve H, Gregory S. Medical therapy for pulmonary arterial hypertension. Chest, 2004, 126: 35-62.
  • 3Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus, 2000, 9: 338-342.
  • 4Johnson SR, Gladman DD, Urowitz MB, et al. Pulmonary hypertension in systemic lupus. Lupus, 2004, 13: 506-509.
  • 5Winslow TM, Ossipov MA, Fazio GP, et al. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J, 1995, 129: 510-515.
  • 6McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of Pulmonary Arterial Hypertension. Chest, 2004, 126: 78-92.
  • 7Hinderliter AL, Willis PW, Long W, et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. Am J Cardiol, 1999, 84: 481-484.
  • 8Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coil Cardiol, 2002, 39: 1214-1219.

共引文献4

同被引文献69

  • 1史坚.浅析系统性硬皮病的胸部x线表现[J].求医问药(下半月),2013(9):168-169. 被引量:1
  • 2徐作军.特发性间质性肺炎的诊治进展[J].中国实用内科杂志,2007,27(1):1-4. 被引量:20
  • 3杨宁,赵成,刘布骏,孙凌云.结缔组织病并发肺动脉高压110例临床分析[J].中华风湿病学杂志,2007,11(9):552-555. 被引量:20
  • 4Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases [ J ]. Semin Respir Crit Care Med, 2009, 30:429-439.
  • 5Amaud L, Agard C, Haroche J, et al. Pulmonary arterial hypertension in systemic lupus erythematosus [ J ]. Rev Med Interne, 2011, 32:689-697.
  • 6Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus : prevalence, predictors and diagnostic strategy[ J]. Autoimmun Rev, 2013 , 12:410-415.
  • 7Kasparian A, Floros A, Gialafos E,et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus[ J]. Lupus,2007,16: 505-508.
  • 8Lian F, Chen D, Wang Y, et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus [ J ]. Rheumatol Int, 2012, 32: 1727-1731.
  • 9Chow SL, Chandran V, Fazelzad R, et al. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension[ J]. Lupus, 2012 ,21:353-364.
  • 10Chung SM, Lee CK, Lee EY, et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension [ J ]. Clin Rheumatol, 2006,25 : 866-872.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部